Literature DB >> 24642644

Reply: Personalization of therapy and polypills.

Ruth Webster1, Anthony Rodgers1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24642644     DOI： 10.1038/nrcardio.2013.185-c2

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  9 in total

1.  Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease.

Authors:  Jasper Jan Brugts; Aaron Isaacs; Eric Boersma; Cock M van Duijn; Andre G Uitterlinden; Willem Remme; Michel Bertrand; Toshiharu Ninomiya; Claudio Ceconi; John Chalmers; Stephen MacMahon; Kim Fox; Roberto Ferrari; Jacqueline C M Witteman; A H Jan Danser; Maarten L Simoons; Moniek P M de Maat
Journal:  Eur Heart J       Date:  2010-06-10       Impact factor: 29.983

Review 2.  Monitoring in chronic disease: a rational approach.

Authors:  Paul Glasziou; Les Irwig; David Mant
Journal:  BMJ       Date:  2005-03-19

3.  Prevention: coronary artery calcium and polypill therapy.

Authors:  Ruth Webster; Anthony Rodgers
Journal:  Nat Rev Cardiol       Date:  2013-11-26       Impact factor: 32.419

4.  Optimizing treatment benefit: individualized therapy or the polypill?

Authors:  Jasper J Brugts
Journal:  Nat Rev Cardiol       Date:  2014-03-18       Impact factor: 32.419

5.  Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.

Authors:  Salim Yusuf; Shofiqul Islam; Clara K Chow; Sumathy Rangarajan; Gilles Dagenais; Rafael Diaz; Rajeev Gupta; Roya Kelishadi; Romaina Iqbal; Alvaro Avezum; Annamarie Kruger; Raman Kutty; Fernando Lanas; Liu Lisheng; Li Wei; Patricio Lopez-Jaramillo; Aytekin Oguz; Omar Rahman; Hany Swidan; Khalid Yusoff; Witold Zatonski; Annika Rosengren; Koon K Teo
Journal:  Lancet       Date:  2011-08-26       Impact factor: 79.321

6.  Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries.

Authors:  Clara K Chow; Koon K Teo; Sumathy Rangarajan; Shofiqul Islam; Rajeev Gupta; Alvaro Avezum; Ahmad Bahonar; Jephat Chifamba; Gilles Dagenais; Rafael Diaz; Khawar Kazmi; Fernando Lanas; Li Wei; Patricio Lopez-Jaramillo; Lu Fanghong; Noor Hassim Ismail; Thandi Puoane; Annika Rosengren; Andrzej Szuba; Ahmet Temizhan; Andy Wielgosz; Rita Yusuf; Afzalhussein Yusufali; Martin McKee; Lisheng Liu; Prem Mony; Salim Yusuf
Journal:  JAMA       Date:  2013-09-04       Impact factor: 56.272

7.  A strategy to reduce cardiovascular disease by more than 80%.

Authors:  N J Wald; M R Law
Journal:  BMJ       Date:  2003-06-28

8.  An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk.

Authors:  Anthony Rodgers; Anushka Patel; Otavio Berwanger; Michiel Bots; Richard Grimm; Diederick E Grobbee; Rod Jackson; Bruce Neal; Jim Neaton; Neil Poulter; Natasha Rafter; P Krishnam Raju; Srinath Reddy; Simon Thom; Stephen Vander Hoorn; Ruth Webster
Journal:  PLoS One       Date:  2011-05-25       Impact factor: 3.240

9.  Long term monitoring in patients receiving treatment to lower blood pressure: analysis of data from placebo controlled randomised controlled trial.

Authors:  Katherine Keenan; Andrew Hayen; Bruce C Neal; Les Irwig
Journal:  BMJ       Date:  2009-04-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.